Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy

BACKGROUND: Clinically localized renal cell carcinoma is treated primarily with surgery followed by observation or adjuvant sunitinib in selected high-risk patients. The checkpoint inhibitor immunotherapeutic agents nivolumab and ipilimumab have recently shown a survival benefit in the first-line me...

Descripción completa

Detalles Bibliográficos
Autores principales: Labbate, Craig, Hatogai, Ken, Werntz, Ryan, Stadler, Walter M., Steinberg, Gary D., Eggener, Scott, Sweis, Randy F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413449/
https://www.ncbi.nlm.nih.gov/pubmed/30857555
http://dx.doi.org/10.1186/s40425-019-0546-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413449/
https://www.ncbi.nlm.nih.gov/pubmed/30857555
http://dx.doi.org/10.1186/s40425-019-0546-8

Ejemplares similares